New obesity drug IBI362 shows promise in early trial for chinese patients
NCT ID NCT07000955
First seen Dec 16, 2025 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This study tests a new drug called IBI362 in 98 Chinese adults with moderate to severe obesity (BMI ≥ 32.5). Participants receive weekly injections of IBI362, tirzepatide, or a placebo for several weeks. The main goals are to check safety, side effects, and how the drug behaves in the body, while also measuring weight loss. It is an early-stage trial, so results will help decide if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210003, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI362 (a drug similar to tirzepatide, given as a weekly injection)
What this could lead to
If successful, this could point toward a new weight-loss medication for people with severe obesity, offering an alternative to existing treatments.
What could go wrong
This is an early-phase trial with only 98 participants, so results may not apply to everyone. Side effects and safety are still being studied, and the drug may not prove effective or safe in larger trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.